SG11201900090TA - Treatment of cancer - Google Patents

Treatment of cancer

Info

Publication number
SG11201900090TA
SG11201900090TA SG11201900090TA SG11201900090TA SG11201900090TA SG 11201900090T A SG11201900090T A SG 11201900090TA SG 11201900090T A SG11201900090T A SG 11201900090TA SG 11201900090T A SG11201900090T A SG 11201900090TA SG 11201900090T A SG11201900090T A SG 11201900090TA
Authority
SG
Singapore
Prior art keywords
international
california
rule
treatment
applicant
Prior art date
Application number
SG11201900090TA
Inventor
Michael Niesman
Kai Zhang
Original Assignee
Mingsight Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mingsight Pharmaceuticals Inc filed Critical Mingsight Pharmaceuticals Inc
Publication of SG11201900090TA publication Critical patent/SG11201900090TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 1#11101111 0 11101 HOE 3E1 0 0111111 0111 OM 11011101 IMO 1111 HE International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\"1 WO 2018/013862 Al 18 January 2018 (18.01.2018) W I PO I PC T (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, A61K 31/52 (2006.01) C07D 487/04 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, PCT/US2017/042011 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 13 July 2017 (13.07.2017) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 62/362,369 14 July 2016 (14.07.2016) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: MINGSIGHT PHARMACEUTICALS, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, INC. [US/US]; P.O. Box 261208, San Diego, California MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 92196 (US). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (72) Inventors: NIESMAN, Michael; P.O. Box 261208, San KM, ML, MR, NE, SN, TD, TG). Diego, California 92196 (US). ZHANG, Kai; P.O. Box 261208, San Diego, California 92196 (US). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a (74) Agent: FLOYD, Jennifer; Wilson Sonsini Goodrich & Ro- sait, 650 Page Mill Road, Palo Alto, California 94304 (US). — = as to the applicant's entitlement to claim the priority of the patent (Rule 4.17(0 _ Designated States (unless otherwise indicated, for every earlier application (Rule 4.17(iii)) _ (81) kind of national protection available): AE, AG, AL, AM, = _ AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, _ = Title: TREATMENT OF CANCER = (54) = Cell Proliferation cmpd A plus Ibrutinib = —o— —•— 1.25 nM — o — Cmpd A only = 0.3125 nM —0—.625 nM = 120% ,, --- = 0 110% U = = 48 oill11111111111 -112 `• BO% . Q' i i I 1 11 I I I I i • I I , , . J = = _ = 60% --- ji lk lvi = a) 40% 20% — 0_ c.) —......w.m r--- \"• 111 + 4 -...1 1 1.11 ,* Ill • • - 0 0% 0.01 0.10 1.00 N Cm pd A Drug Concentration (OA) GC en ,—, © FIG. 3C 00 1-1 (57) : Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein C:::: ) are compositions and methods for the treatment of Ewings Sarcoma. Said compositions comprise isoform selective pyrrolo-pyrazole el PKC inhibitors. C [Continued on next page] WO 2018/013862 Al MIDEDIMOM0101011EFIENIIEMIDERIEDIDIIIMEHOIS Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event amendments (Rule 48.2(h)) of receipt of
SG11201900090TA 2016-07-14 2017-07-13 Treatment of cancer SG11201900090TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662362369P 2016-07-14 2016-07-14
PCT/US2017/042011 WO2018013862A1 (en) 2016-07-14 2017-07-13 Treatment of cancer

Publications (1)

Publication Number Publication Date
SG11201900090TA true SG11201900090TA (en) 2019-02-27

Family

ID=60953395

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900090TA SG11201900090TA (en) 2016-07-14 2017-07-13 Treatment of cancer

Country Status (8)

Country Link
US (5) US11154555B2 (en)
EP (1) EP3484477B1 (en)
JP (3) JP2019524700A (en)
CN (2) CN109715166A (en)
AU (3) AU2017295858A1 (en)
CA (1) CA3030429A1 (en)
SG (1) SG11201900090TA (en)
WO (1) WO2018013862A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016355303B2 (en) * 2015-11-20 2021-10-07 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
EP3484477B1 (en) 2016-07-14 2023-09-13 Mingsight Pharmaceuticals, Inc. Treatment of cancer
EP4068967A4 (en) * 2019-12-06 2023-12-27 Mingsight Pharmaceuticals, Inc. Compositions comprising pkc-beta inhibitors and processes for the preparation thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786213B2 (en) 2003-10-15 2010-08-31 The Regents Of The University Of California Biomacromolecule polymer conjugates
CA2658263A1 (en) * 2006-07-18 2008-01-24 University Of Rochester Thiadiazolidinone derivatives
UA96618C2 (en) * 2007-02-07 2011-11-25 Пфайзер Инк. 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
KR101060892B1 (en) * 2007-02-07 2011-08-31 화이자 인코포레이티드 3-amino-pyrrolo [3,4-C] pyrazole-5 (1H, 4H, 6H) carbaldehyde derivatives as PPC inhibitors
WO2008125945A2 (en) 2007-04-12 2008-10-23 Pfizer Inc. 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
WO2011120911A1 (en) 2010-03-30 2011-10-06 Novartis Ag Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
EP2906556A1 (en) * 2012-10-11 2015-08-19 Pharmacyclics, Inc. Companion diagnostics for tec family kinase inhibitor therapy
EP2983670A4 (en) 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
US9416131B2 (en) 2014-03-25 2016-08-16 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma
ES2872338T3 (en) 2014-05-23 2021-11-02 Mingsight Pharmaceuticals Inc Treatment of autoimmune diseases
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
EP3484477B1 (en) * 2016-07-14 2023-09-13 Mingsight Pharmaceuticals, Inc. Treatment of cancer
CN112118842A (en) 2018-01-17 2020-12-22 明赛制药股份公司 Combination therapy for cancer treatment

Also Published As

Publication number Publication date
US20190216809A1 (en) 2019-07-18
CA3030429A1 (en) 2018-01-18
EP3484477B1 (en) 2023-09-13
AU2017295858A1 (en) 2019-01-24
US20220202814A1 (en) 2022-06-30
US20220000870A1 (en) 2022-01-06
AU2022201717B2 (en) 2023-07-27
JP2022169593A (en) 2022-11-09
WO2018013862A1 (en) 2018-01-18
CN115381832A (en) 2022-11-25
AU2023237034A1 (en) 2023-10-12
JP2023075161A (en) 2023-05-30
AU2022201717A1 (en) 2022-04-07
JP2019524700A (en) 2019-09-05
EP3484477A1 (en) 2019-05-22
EP3484477A4 (en) 2020-03-04
CN109715166A (en) 2019-05-03
US11154555B2 (en) 2021-10-26
US20210401837A1 (en) 2021-12-30
US20220202815A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201909011PA (en) Niraparib compositions
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201407200TA (en) Liquid formulation
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201809882XA (en) Pharmaceutical combinations for treating cancer